The field of cardio-oncology and the potential for subsequent cardiotoxicity in patients receiving cancer care – becoming symptomatic perhaps as late as five to ten years post-treatment – have become better known by clinicians in recent years. Researchers in Spain crystallized the link some 13 years ago.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?